Our Pipeline

Breadth and Quality

PetMedix’s pipeline is multi-species, embodies multiple formats, and addresses a breadth of different targets and indications. All assets here were developed by PetMedix scientists at our Cambridge laboratory, and are wholly owned by PetMedix.

Species Indication Target Peak Revenue (USA) Stage Target Selection & Validation Function Screening in vitro, ex vivo Pre-clinical Proof of concept in vivo Development
PET001 Dog B Cell Lymphoma CD20 $30-50M Development
PET002 Dog Immuno-oncology Undisclosed $30-50M Development
PET003 Dog Atopic Dermatitis OX40L >$100M Development
PET004 Dog B Cell Lymphoma 'bi-specific' $30-50M Development
PET005 Dog Pain p75-Fc >$100M Development
PET006 Cat Chronic Kidney Disease Undisclosed $30-50M Target Selection & Validation
PET007 Cat Pain p75-Fc $30-50M Function Screening in vitro, ex vivo
PET008+ Both Various Undisclosed Target Selection & Validation
Last updated: July 2023
Scroll to Top